DE69429570D1 - Galanthamin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente - Google Patents

Galanthamin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente

Info

Publication number
DE69429570D1
DE69429570D1 DE69429570T DE69429570T DE69429570D1 DE 69429570 D1 DE69429570 D1 DE 69429570D1 DE 69429570 T DE69429570 T DE 69429570T DE 69429570 T DE69429570 T DE 69429570T DE 69429570 D1 DE69429570 D1 DE 69429570D1
Authority
DE
Germany
Prior art keywords
compounds
galanthamine
medicines
derivatives
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69429570T
Other languages
English (en)
Other versions
DE69429570T2 (de
Inventor
Kosley, Jr
Larry Davis
Veronica Taberna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69429570D1 publication Critical patent/DE69429570D1/de
Publication of DE69429570T2 publication Critical patent/DE69429570T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69429570T 1993-10-15 1994-10-10 Galanthamin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente Expired - Lifetime DE69429570T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/137,444 US6316439B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (2)

Publication Number Publication Date
DE69429570D1 true DE69429570D1 (de) 2002-02-07
DE69429570T2 DE69429570T2 (de) 2002-08-29

Family

ID=22477461

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69429570T Expired - Lifetime DE69429570T2 (de) 1993-10-15 1994-10-10 Galanthamin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente

Country Status (23)

Country Link
US (1) US6316439B1 (de)
EP (1) EP0649846B1 (de)
JP (1) JP2664343B2 (de)
KR (1) KR100227957B1 (de)
CN (1) CN1039910C (de)
AT (1) ATE211474T1 (de)
AU (1) AU696170B2 (de)
CA (1) CA2118172C (de)
CZ (1) CZ283731B6 (de)
DE (1) DE69429570T2 (de)
DK (1) DK0649846T3 (de)
EG (1) EG20726A (de)
ES (1) ES2170759T3 (de)
FI (1) FI108722B (de)
IL (1) IL111275A (de)
NO (1) NO307464B1 (de)
NZ (1) NZ264682A (de)
PL (1) PL177549B1 (de)
PT (1) PT649846E (de)
RO (1) RO114134B1 (de)
RU (1) RU2109743C1 (de)
TW (1) TW289754B (de)
ZA (1) ZA948061B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
WO2001043697A2 (en) * 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
CN100343258C (zh) * 2001-04-30 2007-10-17 美国拜尔公司 新的4－氨基－5,6－取代的噻吩并[2,3－d]嘧啶化合物
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20040254146A1 (en) * 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
WO2006071274A2 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
EP1895995A2 (de) * 2005-05-13 2008-03-12 Alza Corporation Mehrschichtige transdermale systeme zur galantamine abgabe
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US20070104771A1 (en) * 2005-09-23 2007-05-10 Jay Audett Transdermal galantamine delivery system
DK2137192T3 (da) 2008-04-14 2014-05-26 Neurodyn Life Sciences Inc Derivater af galantamin som prodrugs til behandling af humane hjernesygdomme
AU2010275431A1 (en) * 2009-07-23 2012-02-23 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof
US11219627B2 (en) * 2014-05-16 2022-01-11 Synaptec Development Llc Clearance of amyloid beta
EP4029867A1 (de) 2021-01-13 2022-07-20 Alpha Cognition Inc. Feste formen von galantaminbenzoat-gluconat

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
ATE411026T1 (de) * 1987-05-04 2008-10-15 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
ATE183084T1 (de) 1991-05-14 1999-08-15 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
EP0649846A1 (de) 1995-04-26
ATE211474T1 (de) 2002-01-15
PT649846E (pt) 2002-06-28
NO943895D0 (no) 1994-10-14
NZ264682A (en) 1995-07-26
AU7581394A (en) 1995-05-04
RU94036745A (ru) 1996-12-10
JPH07188239A (ja) 1995-07-25
KR100227957B1 (ko) 1999-11-01
DK0649846T3 (da) 2002-04-15
IL111275A0 (en) 1994-12-29
DE69429570T2 (de) 2002-08-29
CZ254594A3 (en) 1995-07-12
CA2118172C (en) 2000-01-04
IL111275A (en) 2003-01-12
CZ283731B6 (cs) 1998-06-17
PL305457A1 (en) 1995-04-18
US6316439B1 (en) 2001-11-13
ZA948061B (en) 1995-06-06
RO114134B1 (ro) 1999-01-29
CA2118172A1 (en) 1995-04-16
AU696170B2 (en) 1998-09-03
TW289754B (de) 1996-11-01
ES2170759T3 (es) 2002-08-16
CN1108657A (zh) 1995-09-20
NO943895L (no) 1995-04-18
CN1039910C (zh) 1998-09-23
FI108722B (fi) 2002-03-15
PL177549B1 (pl) 1999-12-31
NO307464B1 (no) 2000-04-10
RU2109743C1 (ru) 1998-04-27
FI944823A (fi) 1995-04-16
EG20726A (en) 1999-12-29
FI944823A0 (fi) 1994-10-13
KR950011445A (ko) 1995-05-15
JP2664343B2 (ja) 1997-10-15
EP0649846B1 (de) 2002-01-02

Similar Documents

Publication Publication Date Title
DE69429570D1 (de) Galanthamin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente
HUT71548A (en) Tricyclic benzazepine and benzazocine derivatives, pharmaceutical compositions of vasopressin antagonistic activity containing them and process for preparing said compounds
IL109526A0 (en) Benzofuranyl- and thiophenyl-alkanecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
ATE129503T1 (de) Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien.
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
DK1004578T3 (da) 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
DE3775882D1 (de) Substituierte 6-fluor-4-oxo-1,4-dihydrochinolin-3-carbonsaeuren ; deren derivate; diese verbindung enthaltende pharmazeutische zubereitungen und verfahren zur herstellung dieser verbindungen.
ATE227293T1 (de) 2,3-disubstituierte-(5,6)-heteroarylkondensiert - pyrimidin-4-one
DE69008142T2 (de) 4-Substituierten Imidazolen zur Senkung des intraokularen Druckes.
ATE164578T1 (de) Verzweigte aminothiazole-derivate, verfahren zu ihrer herstellung und pharmazeutische zusammenstellungen die sie enthalten
DE3864636D1 (de) Amidverbindungen, verfahren zu ihrer herstellung und zusammensetzung zur aktivierung gastromotorischer funktionen.
DE3780015D1 (de) Kondensierte heterocyclische tetrahydroaminochinolinole und verwandte verbindungen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
HUT70761A (en) Alkyl derivatives of trazodone having action for central nervous system, pharmaceutical compositions for preparing thereof
ATE42291T1 (de) Spiro(indolo(1,7-ab>(1,5>benzodiazepin-2,4'piperidine> und zwischenprodukte, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel.
ATE100463T1 (de) Renin-hemmende aminooligohydroxy-derivate.
WO2000008006A3 (en) Piperidine and piperazine derivatives, process for their preparation and pharmaceutical compounds containing them
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
ATE6648T1 (de) 4h-benzo(4,5)cyclohepta(1,2-b)furanderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
DE69322218D1 (de) Heteroarenylpiperazine, Verfahren zu ihrer Herstellung und ihre Anwendung als Medikamente
DE3761252D1 (de) Pregnane derivate, verfahren zu ihrer herstellung und pharmazeutische zusammenstellungen, die sie enthalten.
DE59905342D1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition